Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

Emily S. Lau, Elizabeth Liu, Samantha M. Paniagua, Amy A. Sarma, Giovanna Zampierollo, Begoña López, Javier Díez, Thomas J. Wang, Jennifer E. Ho

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


We investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3 levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further investigation.

Original languageEnglish (US)
Pages (from-to)12-21
Number of pages10
JournalJACC: Basic to Translational Science
Issue number1
StatePublished - Jan 2021


  • cardiac fibrosis
  • galectin-3
  • heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension'. Together they form a unique fingerprint.

Cite this